Research Grade Anti-Human CD124/IL4R/IL-4Rα (MEDI9314) (HB732116)

Datasheet Share product Copy info

Price(USD): $

Spec:

100ug
1mg

Number:

Overview
Images
References
Datasheet

Overview

Catalog No.	HB732116
Description	Anti-Human CD124/IL4R/IL-4Rα (MEDI9314) (HB732116) is a research-grade recombinant antibody targeting CD124. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Species reactivity	Human
Applications	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Host species	Human
Isotype	IgG
Clone ID	MEDI9314
Expression system	Mammalian Cells
Clonality	Monoclonal
Target	IL-4RA, IL-4-binding protein, IL-4 receptor subunit alpha, Soluble IL-4R-alpha, IL4-BP, IL4R, IL-4R subunit alpha, IL-4R-alpha, CD124, Interleukin-4 receptor subunit alpha, IL4RA, Soluble IL-4 receptor subunit alpha, sIL4Ralpha/prot
Endotoxin level	Please contact the lab for this information.
Purity	>95% purity as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Accession	P24394
Form	Liquid
Storage buffer	0.01M PBS, pH 7.4. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Alternate Names	MEDI9314
Background	Interleukin-4 receptor subunit alpha (CD124/IL4R) is a ~89 kDa protein. Receptor for both interleukin 4 and interleukin 13. Couples to the JAK1/2/3-STAT6 pathway. The IL4 response is involved in promoting Th2 differentiation. The IL4/IL13 responses are involved in regulating IgE production and, chemokine and mucus production at sites of allergic inflammation. In certain cell types, can signal through activation of insulin receptor substrates, IRS1/IRS2. CD124 is the therapeutic target of dupilumab (Dupixent). 1. Andrews, AL. et al. (2006) The Journal of allergy and clinical immunology 118, 858-65. PMID: 17030238
Note	For research use only. Not suitable for clinical or therapeutic use.